| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer K Miller, M Wang, J Gralow, M Dickler, M Cobleigh, EA Perez, T Shenkier, ... New England journal of medicine 357 (26), 2666-2676, 2007 | 3785 | 2007 |
| Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer KD Miller, LI Chap, FA Holmes, MA Cobleigh, PK Marcom, ... Journal of clinical oncology 23 (4), 792-799, 2005 | 1719 | 2005 |
| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 798 | 2018 |
| Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification AD Seidman, MN Fornier, FJ Esteva, L Tan, S Kaptain, A Bach, ... Journal of Clinical Oncology 19 (10), 2587-2595, 2001 | 755 | 2001 |
| Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with … BP Schneider, M Wang, M Radovich, GW Sledge, S Badve, A Thor, ... Journal of Clinical Oncology 26 (28), 4672, 2008 | 719 | 2008 |
| Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline HS Rugo, RB Rumble, E Macrae, DL Barton, HK Connolly, MN Dickler, ... Journal of Clinical Oncology 34 (25), 3069-3103, 2016 | 654 | 2016 |
| MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer MN Dickler, SM Tolaney, HS Rugo, J Cortés, V Diéras, D Patt, H Wildiers, ... Clinical Cancer Research 23 (17), 5218-5224, 2017 | 633 | 2017 |
| HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing … S Modi, A Stopeck, H Linden, D Solit, S Chandarlapaty, N Rosen, ... Clinical Cancer Research 17 (15), 5132-5139, 2011 | 492 | 2011 |
| Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans S Titus, F Li, R Stobezki, K Akula, E Unsal, K Jeong, M Dickler, M Robson, ... Science translational medicine 5 (172), 172ra21-172ra21, 2013 | 480 | 2013 |
| Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing D Mandelker, L Zhang, Y Kemel, ZK Stadler, V Joseph, A Zehir, ... Jama 318 (9), 825-835, 2017 | 449 | 2017 |
| Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence C Yang, Z Li, T Bhatt, M Dickler, D Giri, M Scaltriti, J Baselga, N Rosen, ... Oncogene 36 (16), 2255-2264, 2017 | 351 | 2017 |
| PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ... Science translational medicine 7 (283), 283ra51-283ra51, 2015 | 341 | 2015 |
| Lower-dose vs high-dose oral estradiol therapy of hormone receptor–positive, aromatase inhibitor–resistant advanced breast cancer: A phase 2 randomized study MJ Ellis, F Gao, F Dehdashti, DB Jeffe, PK Marcom, LA Carey, MN Dickler, ... Jama 302 (7), 774-780, 2009 | 324 | 2009 |
| Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 … IE Krop, IA Mayer, V Ganju, M Dickler, S Johnston, S Morales, DA Yardley, ... The lancet oncology 17 (6), 811-821, 2016 | 289 | 2016 |
| Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival KD Miller, T Weathers, LG Haney, R Timmerman, M Dickler, J Shen, ... Annals of oncology 14 (7), 1072-1077, 2003 | 276 | 2003 |
| PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D E Toska, HU Osmanbeyoglu, P Castel, C Chan, RC Hendrickson, ... Science 355 (6331), 1324-1330, 2017 | 250 | 2017 |
| Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors N Vasan, P Razavi, JL Johnson, H Shao, H Shah, A Antoine, E Ladewig, ... Science 366 (6466), 714-723, 2019 | 223 | 2019 |
| PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition P Castel, H Ellis, R Bago, E Toska, P Razavi, FJ Carmona, S Kannan, ... Cancer cell 30 (2), 229-242, 2016 | 220 | 2016 |
| When you look matters: the effect of assessment schedule on progression-free survival KS Panageas, L Ben-Porat, MN Dickler, PB Chapman, D Schrag Journal of the National Cancer Institute 99 (6), 428-432, 2007 | 204 | 2007 |
| Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer MN Dickler, MA Cobleigh, KD Miller, PM Klein, EP Winer Breast cancer research and treatment 115, 115-121, 2009 | 169 | 2009 |
